Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
制药和医疗保健在改期后的大麻方面会有竞争优势吗？数据分析专家权衡
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.
BDSA首席执行官罗伊·宾厄姆预计，美国大麻市场将大幅增长，预计到2028年销售额将达到近460亿美元。
This growth would be primarily fueled by the expansion of adult-use markets and adoption of new licensed and regulated markets, both medical and recreational. Key states driving this surge include New York, New Jersey and potentially Florida and Ohio, Bingham says.
这种增长将主要由成人用途市场的扩大以及医疗和娱乐等新的许可和监管市场的采用来推动。宾厄姆说，推动这种激增的主要州包括纽约、新泽西州，可能还有佛罗里达州和俄亥俄州。
Influence Of DEA Rescheduling
缉毒局改期的影响
Following the DEA's decision to reclassify cannabis to Schedule III, Bingham predicts this will open up new avenues for medical research and investment. "We expect major medical discoveries within five years," he...
在缉毒局决定将大麻重新归类为附表三之后，宾厄姆预测这将为医学研究和...
登录免费看全文
登录/注册